- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05627765
An Integrated Smoking Cessation and Alcohol Intervention for Young People
July 2, 2025 updated by: Dr Eva Ho, The Hong Kong Polytechnic University
An Integrated Smoking Cessation and Alcohol Intervention Among Hong Kong Chinese Young People: A Feasibility Randomized Controlled Trial
The specific objectives of this study are to investigate the (1) feasibility, (2) preliminary effectiveness and (3) effect sizes of the integrated smoking cessation and alcohol intervention when compared to standalone smoking cessation (ST) and control among young adults in Hong Kong.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hongkong, Hong Kong
- The Hong Kong Polytechnic University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 21 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- aged 18 to 25 years
- smoked at least one traditional cigarette in the past 30 days
- consumed at least one alcohol unit (one "alcohol unit" contains 10g of pure alcohol) in the past 30 days
- speak Cantonese.
Exclusion Criteria:
- have a compromised mental status and/or communication problems
- participating in other smoking cessation and/or alcohol interventions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control arm
Participants will be provided with two leaflets designed by Department of health: one for smoking cessation and another for alcohol abstinence.
|
|
|
Experimental: Standard treatment (ST) arm
Participants will receive a brief smoking cessation intervention based on the "5A" and "5R" models proposed by the World Health Organization.
The "STAR" method as quitting skills will also be provided.
The "5A" model includes five steps to identify participants who are ready to quit smoking.
For those who are ready to quit, a research assistant will assist them to quit using the "STAR" method: Set a quit date within 1 week, Tell the surrounding people that they have planned to quit and solicited their support, Anticipate challenges to quit attempt, and Remove all tobacco products.
Otherwise, the "5R" model will be applied to those not yet ready to quit.
After "5R" is applied, the research assistant will repeat the assessment of their willingness to quit.
The booster interventions will be delivered by the research assistant through follow-ups arranged with the participants via phone.
|
participants who are ready to quit smoking: a brief smoking cessation intervention based on the "5A" models and "STAR" method as quitting skills. participants who are not yet ready to quit smoking: a brief smoking cessation intervention based on the "5R" models. |
|
Experimental: Integrated Intervention (II) arm
In addition to the brief smoking cessation intervention based on the "5A" and "5R" models, participants in this arm received brief advice on alcohol use based on the "FRAMES" model.
The booster interventions will be delivered by the research assistant through follow-ups arranged with the participants via phone.
|
brief advice on alcohol use based on the "FRAMES" model and the brief smoking cessation intervention based on the "5A" and "5R" models.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
screening rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of smokers screened divided by the number of smokers available for screening
|
From screening to the end of treatment after 6 months
|
|
eligibility rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of eligible smokers divided by the number of screened people
|
From screening to the end of treatment after 6 months
|
|
consent rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of eligible smokers who agree to participate divided by the number of eligible smokers
|
From screening to the end of treatment after 6 months
|
|
randomization rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of participants who are randomized divided by the number of eligible smokers who consent to participate
|
From screening to the end of treatment after 6 months
|
|
attendance rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of participants who complete the intervention divided by the number of participants who are randomized into the treatment arms (ST and II)
|
From screening to the end of treatment after 6 months
|
|
adherence to intervention
Time Frame: From screening to the end of treatment after 6 months
|
the number of participants in the two treatment arms who practice the skills learned during the intervention divided by the number of participants in the two treatment arms
|
From screening to the end of treatment after 6 months
|
|
retention rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of participants who remain in the study divided by the number of participants randomized
|
From screening to the end of treatment after 6 months
|
|
completion rate
Time Frame: From screening to the end of treatment after 6 months
|
the number of participants who complete the questionnaire divided by the number of questionnaires distributed
|
From screening to the end of treatment after 6 months
|
|
missing data
Time Frame: From screening to the end of treatment after 6 months
|
the percentage of missing data
|
From screening to the end of treatment after 6 months
|
|
adverse events
Time Frame: From screening to the end of treatment after 6 months
|
unfavorable or unintended events during the study period that were not present at baseline or appear to have worsened since baseline
|
From screening to the end of treatment after 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smoking quit rate
Time Frame: From screening to the end of treatment after 6 months
|
the effect size of II on self-reported and biochemically validated quit rates for smoking at 6 months relative to ST and Control.
|
From screening to the end of treatment after 6 months
|
|
alcohol quit rate
Time Frame: From screening to the end of treatment after 6 months
|
the effect size of II on self-reported quit rate for alcohol at 6 months relative to ST and Control
|
From screening to the end of treatment after 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ka Yan Ho, The Hong Kong Polytechnic University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Actual)
December 31, 2024
Study Completion (Actual)
December 31, 2024
Study Registration Dates
First Submitted
April 13, 2022
First Submitted That Met QC Criteria
November 24, 2022
First Posted (Actual)
November 28, 2022
Study Record Updates
Last Update Posted (Estimated)
July 8, 2025
Last Update Submitted That Met QC Criteria
July 2, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19200161
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
Penn State UniversityNot yet recruiting
-
Boston University Charles River CampusActive, not recruiting
-
The Hong Kong Polytechnic UniversityNot yet recruitingHazardous Drinking | Harmful Alcohol Use
-
University of WyomingRecruiting
-
Binghamton UniversityNot yet recruitingUnderage Drinking | Drinking, Teen | Adolescent Alcohol UseUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
The University of Hong KongRecruitingmHealth Intervention | AlcoholHong Kong
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
Clinical Trials on Standard treatment (ST) arm
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Icahn School of Medicine at Mount SinaiNot yet recruiting
-
Abbott Medical DevicesCompletedAtrial Fibrillation | BradycardiaGermany
-
Brown UniversityCompleted
-
Institut Claudius RegaudInstitute of Cancer Research, United Kingdom; Hellenic Cooperative Oncology... and other collaboratorsRecruitingAdenocarcinoma | Cervical Carcinoma | Adenosquamous CarcinomaFrance, Italy, Spain, Czechia
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedCocaine Related DisordersBrazil
-
MD Stem CellsRecruitingGlaucoma | Age-Related Macular Degeneration | Macular Degeneration | Retinitis Pigmentosa | Leber Hereditary Optic Neuropathy | Optic Atrophy | Blindness | Optic Neuropathy | Vision, Low | Retinal Disease | Stargardt Disease | Maculopathy | Retinopathy | Optic Nerve Disease | Nonarteritic Ischemic Optic Neuropathy | Vision... and other conditionsUnited States, Austria, United Arab Emirates
-
Association Francaise pour la Recherche ThermaleUniversité Joseph Fourier; Université Victor Segalen Bordeaux 2; HAT Consultant; AXONAL S.A...Completed
-
University of WashingtonNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedFibromyalgiaUnited States